Evaluation of the Effectiveness of Secukinumab in Patients With Moderate to Severe Plaque Psoriasis

Completed

Conditions studied: Plaque Psoriasis

In brief

This study was a real-life study which was based on secondary data collection from the electronic or paper medical records from the Dermatology Clinics of the 14 University, Training \& Research Hospitals in Turkey. Data were extracted between 02 September 2020 and 29 April 2021.

Key facts

Study ID

NCT05344482

Run by

Novartis Pharmaceuticals

People needed

277

Starts

2020-07-09

Expected to finish

2021-08-31

Last updated by the study team

2022-07-01

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• A diagnosis of psoriasis
• Age ≥ 18 years at registry baseline.
• Patients with a firm diagnosis of chronic plaque psoriasis for at least 6 months before enrollment
• Secukinumab treatment should be initiated 52 weeks before data collection date
• Moderate to severe plaque psoriasis with PASI score of ≥10 before initiating secukinumab.

You may not qualify if…

• Patients diagnosed with others types of psoriasis (pustular psoriasis, erythrodermic psoriasis etc) are excluded.
• Previous exposure to secukinumab or any other biologic drug directly targeting IL-17A or IL-17RA

Where it is running

• Novartis Investigative Site — East Hanover, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.